Providing IPT to people living with HIV does not increase the risk of

Providing IPT to people living with HIV does not increase the risk of
developing isoniazid (INH)-resistant TB. Therefore, concerns regarding
the development of INH resistance should not be a barrier to providing
IPT.
Children living with HIV who do not have poor weight gain,4 fever or
current cough are unlikely to have active TB.
Children living with HIV who have any one of the following symptoms –
poor weight gain, fever, current cough or contact history with a TB case
– may have TB and should be evaluated for TB and other conditions.
If the evaluation shows no TB, such children should be offered IPT
regardless of their age.
Children living with HIV who are more than 12 months of age and who
are unlikely to have active TB on symptom-based screening, and have
no contact with a TB case should receive six months of IPT (10 mg/kg/
day) as part of a comprehensive package of HIV prevention and care
services.
In children living with HIV who are less than 12 months of age, only
those children who have contact with a TB case and who are evaluated
for TB (using investigations) should receive six months of IPT if the
evaluation shows no TB disease.
All children living with HIV who have successfully completed treatment
for TB disease should receive INH for an additional six months.